Aleph Farms Submits First Ever Application for Cultivated Meat in Europe
Aleph Farms, a cellular agriculture company that enhances sustainability, food security and animal welfare in our food systems, today announced that it has submitted an application for regulatory approval to the Swiss Federal Food Safety and Veterinary Office (FSVO) with the goal of selling the world’s first cultivated beef steaks under the Aleph Cuts brand in Switzerland. The submission is part of Aleph’s collaboration with Migros, Switzerland’s largest food enterprise, which has been instrumental in assessing the country’s specific regulatory approval process.
Aleph Farms is leveraging the expertise and infrastructure of leaders in food production, including Migros, which first invested in the company in 2019, to help accelerate scale-up, go-to-market activities and commercialization of Aleph Cuts worldwide. Together, Aleph and Migros have since conducted extensive consumer research in Switzerland and navigated the intricacies of the country’s regulatory landscape for novel foods. As part of their agreement, the two companies will continue to develop a go-to-market strategy that involves distribution and commercialization of Aleph Cuts through fine dining food service channels in Switzerland.
“Food systems affect everyone, and it will take a coordinated effort between regulators, innovators and incumbents to ensure food security in a way that helps humanity live within its planetary boundaries,” said Didier Toubia, Co-Founder and CEO of Aleph Farms. “At Aleph Farms, we carefully consider partnerships that reflect our core values and sustainability commitments. Together with Migros, we are establishing the cow cell as the third category of food products from cattle, alongside beef and milk. We look forward to working closely with Switzerland's Federal Food Safety and Veterinary Office to enable access to both high-quality nutrition and world-changing innovation.”
Switzerland is a country with a high affinity for innovation. According to research conducted jointly by Aleph Farms and Migros, 74% of Swiss consumers are open to trying cultivated meat and are motivated to try it chiefly by curiosity and a desire to align with principles like sustainability and animal welfare.
Alongside sustainable animal agriculture, cellular agriculture can help increase resilience and stability in the supply of animal proteins and fats to diners in Switzerland. In addition, acceptance by Swiss consumers – known for a quality-conscious attitude towards food – can contribute further to cultivated meat’s growing momentum worldwide.
Later this year, Aleph Farms plans to launch Aleph Cuts in Singapore and Israel in limited quantities and offer exclusive tasting experiences curated with select partners, pending regulatory approvals. Aleph’s regulatory team is working in similar fashion with regulatory authorities in numerous markets around the world, including Switzerland, in order to ensure compliance with respective safety requirements.
About Aleph Farms
Aleph Farms, an Israel-based cellular agriculture company, enhances sustainability, food security and animal welfare in our food systems by diversifying the supply and decentralizing the production of quality animal proteins and fats as a complement to sustainable animal agriculture.
Founded in 2017, the company unveiled the world’s first cultivated thin-cut beef steak in 2018, the world’s first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts, the company is launching its first product, the cultivated Petit Steak, grown from non-modified cells of a premium Black Angus cow.
For its contributions to climate leadership including a net zero commitment made in 2020, the company has received top accolades from the World Economic Forum and the United Nations.
For more information, follow Aleph Cuts on Instagram and Facebook, Aleph Farms on Twitter and Linkedin, or visit www.aleph-farms.com. Access our press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726122722/en/
Contact information
Natalee Gibson
alephfarms@songuepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 09:10:00 EET | Press release
Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where smart home and in-car connectivity adoption is among the highest globally, focused on four core themes: How consumers use audio across both home and in-car environments Their expect
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 08:01:00 EET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 06:00:00 EET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 04:50:00 EET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint10.12.2025 00:00:00 EET | Press release
Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, government organizations, hyperscalers and other consumers of state-of-the-art digital infrastructure. With these investments, Argo has supported the national expansion of TierPoint’s data center platform, and its efforts to meet and exceed customers’ r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
